☆ 4.7 Article

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel et al.

Summary: Remdesivir and its parent nucleoside, molnupiravir and its parent nucleoside, and the viral protease inhibitor nirmatrelvir have equipotent antiviral activity against the ancestral SARS-CoV2 strain and the variants of concern including Omicron.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

Brandi N. Williamson et al.

Summary: This study demonstrates that early subcutaneous administration of remdesivir can reduce the risk of lower respiratory tract disease caused by SARS-CoV-2 infection.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis

Daniele Focosi et al.

Summary: Despite massive usage, the global level of remdesivir resistance is very low during the COVID-19 pandemic.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Letter Cell Biology

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Pengfei Li et al.

CELL RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

Calvin J. Gordon et al.

Summary: The antiviral effects of Remdesivir (RDV) are strongly correlated with its efficient incorporation of RDV-TP. Inhibition in primer extension reactions is often inefficient at higher NTP concentrations, while template-dependent inhibition of UTP incorporation opposite the embedded RDV-MP is seen with all polymerases.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Chemistry, Medicinal

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models

Yingjun Li et al.

Summary: The article reports that the parent nucleoside of remdesivir, GS-441524, shows potent inhibition of SARS-CoV-2 replication and has high efficacy in reducing viral titers in infected organs without notable toxicity in animal studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

Alexander Muik et al.

Summary: This study tested the neutralizing ability of sera from participants who received two or three doses of the BNT162b2 COVID-19 vaccine against different SARS-CoV-2 variants. The results showed that after two doses, the neutralizing ability against Omicron was significantly reduced, but a third dose effectively increased the neutralizing ability. This suggests that three doses of the vaccine may provide protection against Omicron-mediated COVID-19.

SCIENCE (2022)

添加到收藏夹

Article Cell Biology

Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection

Meghan S. Vermillion et al.

Summary: The pharmacokinetics and efficacy of inhaled Remdesivir (RDV) were investigated in African green monkeys (AGM). Inhalation RDV dosing produced comparable concentrations of the active triphosphate in lower respiratory tract tissues compared to intravenous RDV dosing but resulted in lower systemic exposures. An efficacy study in AGM showed reductions in viral replication in respiratory tract tissues with inhaled RDV dosing, which was similar to intravenous RDV dosing.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Immunology

SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells

Hanjun Zhao et al.

Summary: The Omicron variant of SARS-CoV-2 has distinct virological characteristics compared to the Delta variant. It replicates more slowly and its entry pathway is mediated primarily through the endocytic pathway instead of TMPRSS2 pathway. This difference in entry pathway may have implications for the clinical manifestations or severity of the disease.

EMERGING MICROBES & INFECTIONS (2022)

添加到收藏夹

Article Cell Biology

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice

Alexandra Schafer et al.

Summary: Despite the availability of COVID-19 vaccines, the pandemic remains uncontrolled, underscoring the need for effective antivirals. This study demonstrates the antiviral activity and therapeutic efficacy of GS-621763 against SARS-CoV-2 and MERS-CoV, highlighting its potential as an oral antiviral treatment for COVID-19.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Microbiology

The coronavirus proofreading exoribonuclease mediates extensive viral recombination

Jennifer Gribble et al.

Summary: Recombination is essential for coronavirus diversity and the emergence of new strains. The mechanisms of CoV recombination are not well understood, but studies have shown extensive and diverse recombination products in CoVs during replication. The nsp14-ExoN protein is crucial for native recombination in CoVs, highlighting its potential as a target for inhibitors to control SARS-CoV-2 and future emerging zoonotic CoVs.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Biochemical Research Methods

Engineering SARS-CoV-2 using a reverse genetic system

Xuping Xie et al.

Summary: Reverse genetic system for SARS-CoV-2 is essential for studying viruses, developing vaccines, and screening antiviral drugs. However, manipulating the system is complex due to the large size of the coronavirus genome and toxic genomic elements, requiring a meticulous six-step process. Mastering this system will accelerate COVID-19 research across different scientific fields.

NATURE PROTOCOLS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets

Robert M. Cox et al.

Summary: Remdesivir is an antiviral drug approved for COVID-19 treatment, but its intravenous administration limits wider use. A study has shown that GS-621763, an oral prodrug of remdesivir parent nucleoside GS-441524, has good oral bioavailability and inhibits SARS-CoV-2 and variants of concern in ferrets, demonstrating therapeutic efficacy in a relevant animal model of SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir

Ross Martin et al.

Summary: The study reveals low genetic variation in the RNA replication complex of SARS-CoV-2, especially the RNA-dependent RNA polymerase (nsp12), which is the main target of remdesivir. The risk of pre-existing resistance to remdesivir is minimal.

ANTIVIRAL RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Nicole L. Washington et al.

Summary: The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has been spreading in the United States with multiple introductions as early as late November 2020. The variant shows a logistic growth rate with roughly weekly doubling and increased transmission, requiring immediate action to minimize COVID-19 morbidity and mortality.

CELL (2021)

添加到收藏夹

Article Chemistry, Medicinal

Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV

Richard L. Mackman et al.

Summary: A discovery program identified C-nucleoside 4 as a potential lead compound for respiratory syncytial virus (RSV), which led to the discovery of the more potent drug remdesivir. In vitro metabolism studies confirmed the rapid formation of the active metabolite 1-NTP, and in vivo studies in monkeys showed significant reduction in lung viral load following administration of remdesivir. These early data supported the potential of remdesivir as a novel treatment for RSV prior to its development for other diseases.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

Thuc Nguyen Dan Do et al.

Summary: In this study, using in vitro models of human airway epithelial cells, it was found that remdesivir, GS-441524, EIDD-1931, and IFN showed dose-dependent inhibition of SARS-CoV-2 viral replication, while AT-511 did not inhibit viral replication as expected. These results provide a reference for further screening of SARS-CoV-2 inhibitors.

ANTIVIRAL RESEARCH (2021)

添加到收藏夹

Article Cell Biology

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

David R. Martinez et al.

Summary: Research shows that a combination of two mAbs in clinical trials has strong antiviral effects and therapeutic efficacy against certain variants, while combining RDV and antibodies slightly improves treatment outcomes, supporting the continued use of RDV to treat SARS-CoV-2 infections.

CELL REPORTS (2021)

添加到收藏夹

Article Microbiology

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Agnieszka M. Szemiel et al.

Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Virology

Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool

Aine O'Toole et al.

Summary: The global virus genomics community has responded unprecedentedly to the SARS-CoV-2 pandemic, leading to significant advances in 'real-time' generation and sharing of genomic data. The development of new analytical methods, such as pangolin, has been necessary to handle the rapid growth in virus genome data production. Pangolin has processed nearly two million virus genomes, aiding in SARS-CoV-2 genomic epidemiology and providing researchers with valuable information about the pandemic's transmission lineages.

VIRUS EVOLUTION (2021)

添加到收藏夹

Article Medicine, General & Internal

Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England

Swapnil Mishra et al.

Summary: Since late March 2021, the percentage of non-B.1.1.7 variants has been increasing in London and other English regions, driven by a variety of lineages with immune escape. From mid-April, B.1.617.2 (WHO label Delta) spread rapidly, becoming the dominant variant in England by late May. The competition between variants and the rise of non-B.1.1.7 variants underscore the importance of diverse data sources in community surveillance for early detection of new variants.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Immunology

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection

Zi-Wei Ye et al.

Summary: Research shows that methylprednisolone alone and in combination with remdesivir have beneficial effects in the hamster model of SARS-CoV-2 infection, preventing weight loss, inflammation, and reducing viral loads. Combining anti-inflammatory and antiviral therapy may offer a more effective and safer treatment option for COVID-19, supporting further clinical trials to test the efficacy of methylprednisolone and remdesivir combination therapy.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Emmie de Wit et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Microbiology

An Infectious cDNA Clone of SARS-CoV-2

Xuping Xie et al.

CELL HOST & MICROBE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Wenhao Dai et al.

SCIENCE (2020)

添加到收藏夹

Article Cell Biology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex

James Chen et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Brandi N. Williamson et al.

NATURE (2020)

添加到收藏夹

Article Cell Biology

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Andrea J. Pruijssers et al.

CELL REPORTS (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action

Egor P. Tchesnokov et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xuping Xie et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Cell Biology

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Michael K. Lo et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Microbiology

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Maria L. Agostini et al.

MBIO (2018)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Dustin Siegel et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Cell Biology

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Data, disease and diplomacy: GISAID's innovative contribution to global health

Stefan Elbe et al.

GLOBAL CHALLENGES (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Travis K. Warren et al.

NATURE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Applying Physics-Based Scoring to Calculate Free Energies of Binding for Single Amino Acid Mutations in Protein-Protein Complexes

Hege Beard et al.

PLOS ONE (2013)

添加到收藏夹

Article Chemistry, Medicinal

Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides

Aesop Cho et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)

添加到收藏夹

Article Microbiology

Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing

Lance D. Eckerle et al.

PLOS PATHOGENS (2010)

添加到收藏夹

Article Virology

Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2

Yuta Shirogane et al.

JOURNAL OF VIROLOGY (2008)

添加到收藏夹

Article Virology

Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication

EC Mossel et al.

JOURNAL OF VIROLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.